HER2 status-Negative Posts on Medivizor
Navigation Menu

HER2 status-Negative Posts on Medivizor

Evaluating the real-world safety and effectiveness of palbociclib and hormonal therapy in patients with advanced breast cancer.

Evaluating the real-world safety and effectiveness of palbociclib and hormonal therapy in patients with advanced breast cancer.

Posted by on Nov 27, 2021 in Breast cancer | 0 comments

In a nutshell This study investigated whether the combination of hormonal therapy and cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib (Ibrance) was effective in advanced breast cancer in a real-world practice. The authors found that this treatment has similar safety and effectiveness in these patients as shown in clinical trials. Also,...

Read More

Extended therapy with letrozole for 5 years improves survival outcomes in postmenopausal patients with hormone positive early-stage breast cancer.

Extended therapy with letrozole for 5 years improves survival outcomes in postmenopausal patients with hormone positive early-stage breast cancer.

Posted by on Oct 24, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of extended therapy with letrozole (LET; Femara) for 5 years versus the standard therapy of 2-3 years for the treatment of postmenopausal women with early-stage breast cancer (BC). The data showed that extended treatment with LET for 5 years significantly improved the survival outcomes...

Read More

Comparing platinum-based chemotherapy and immunotherapy for the treatment of patients with early-stage triple negative breast cancer.

Comparing platinum-based chemotherapy and immunotherapy for the treatment of patients with early-stage triple negative breast cancer.

Posted by on Sep 12, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) for the treatment of patients with early-stage triple-negative breast cancer (TNBC). The data showed that ICI plus chemotherapy was associated with good outcomes with reduced side effects compared with...

Read More

Could patient-reported outcomes predict survival benefits in patients with advanced breast cancer treated with abemaciclib?

Could patient-reported outcomes predict survival benefits in patients with advanced breast cancer treated with abemaciclib?

Posted by on Jun 13, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the association between patient-reported outcomes (PROs) and survival outcomes in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (BC) treated with abemaciclib (Verzenio). The data showed that the PROs could be a predictor of survival benefits in these patients. Some...

Read More

Sacituzumab govitecan improves survival in metastatic triple-negative breast cancer.

Sacituzumab govitecan improves survival in metastatic triple-negative breast cancer.

Posted by on Jun 12, 2021 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of sacituzumab govitecan (Trodelvy; SG) compared to chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer (mTNBC). The data showed that SG significantly improved the survival outcomes of these patients compared to chemotherapy. Some background...

Read More

Comparing the real-world effectiveness of palbociclib plus letrozole versus letrozole alone in patients with advanced hormone-positive breast cancer

Comparing the real-world effectiveness of palbociclib plus letrozole versus letrozole alone in patients with advanced hormone-positive breast cancer

Posted by on May 16, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the real-world safety and effectiveness of the palbociclib (Ibrance) plus letrozole (Femara) versus letrozole alone in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-negative (HER2-) metastatic breast cancer (MBC). The data concluded that palbociclib in combination with...

Read More

Chemotherapy versus endocrine therapy before surgery for invasive ductal carcinoma of the breast

Chemotherapy versus endocrine therapy before surgery for invasive ductal carcinoma of the breast

Posted by on Apr 18, 2021 in Breast cancer | 0 comments

In a nutshell This study aimed to compare the effectiveness and safety of endocrine therapy (ET) or chemotherapy (CT) before surgery in patients with invasive ductal carcinoma (IDC) of the breast that is hormone receptor (HR) positive (+) and human epidermal growth factor receptor 2 (ERBB2) negative (-). The study concluded CT before...

Read More

Alpelisib and fulvestrant treatment for PIK3CA mutated, hormone receptor-positive, HER2-negative advanced breast cancer

Alpelisib and fulvestrant treatment for PIK3CA mutated, hormone receptor-positive, HER2-negative advanced breast cancer

Posted by on Jan 17, 2021 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the combination of alpelisib (Piqray) and fulvestrant (Faslodex) in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor 2 (HER2) negative, advanced breast cancer (BC).   This study concluded that this combination provided positive outcomes for...

Read More

Evaluating radiation therapy after breast removal surgery for node-positive triple-negative breast cancer.

Evaluating radiation therapy after breast removal surgery for node-positive triple-negative breast cancer.

Posted by on Dec 28, 2020 in Breast cancer | 0 comments

In a nutshell This study was carried out to assess the use of radiotherapy (RT) after mastectomy (surgical removal of the breast) for triple-negative breast cancer (TNBC) that has spread to the lymph nodes. The authors found that RT after surgery was associated with improved survival in patients with larger tumors. Some background Triple-negative...

Read More